[^3]
[^4]
Gene: [MAP2K1](/genes/map2k1)
[^5]
UniProt: [Q02750](https://www.uniprot.org/uniprot/Q02750)
[^6]
PDB ID: 1S3J, 3E4N, 4LMN
[^7]
Molecular Weight: ~43 kDa
[^8]
Subcellular Localization: Cytoplasm, plasma membrane
Protein Family: MAP kinase kinase (MEK) family
MAP2K1 (Mitogen-Activated Protein Kinase Kinase 1), also known as MEK1, is a dual-specificity protein kinase that phosphorylates and activates ERK1 and ERK2 MAP kinases. This kinase is a critical node in the MAPK/ERK signaling pathway, which regulates numerous cellular processes including cell proliferation, differentiation, survival, and synaptic plasticity. MEK1 has been implicated in the pathophysiology of several neurodegenerative diseases.
MEK1 possesses a characteristic kinase domain structure:
- N-terminal Regulatory Region: Contains a nuclear localization signal and docking motifs for ERK interaction
- Kinase Domain: Dual-specificity kinase domain that phosphorylates ERK on both tyrosine and threonine residues
- C-terminal Regulatory Tail: Contains a MAPK docking motif (D-domain) and activation loop
The enzyme exists as a monomer and requires phosphorylation for activation. MEK1 phosphorylates ERK1/2 at specific TEY (Thr-Glu-Tyr) motifs. The crystal structure reveals the inactive conformation with the activation loop blocking the active site.
MEK1 plays essential roles in the nervous system:
- Regulates neuronal differentiation and process outgrowth
- Controls axonal guidance and pathfinding
- Modulates dendritic arborization
- Essential for proper brain development
- Critical for long-term potentiation (LTP) and long-term depression (LTD)
- Regulates AMPA receptor trafficking
- Controls gene expression required for memory formation
- Modulates NMDA receptor signaling
- Mediates neurotrophic factor signaling (BDNF, NGF)
- Protects neurons from apoptotic stimuli
- Regulates cellular stress responses
- Controls autophagy in neurons
- Participates in circadian clock gene regulation
- Links environmental signals to cellular responses
- MEK/ERK signaling is dysregulated in AD brains
- Elevated ERK activity associated with tau phosphorylation
- Regulates amyloid-beta-induced synaptic dysfunction
- Involved in memory consolidation deficits
- May contribute to neuronal apoptosis
- MEK signaling modulates dopaminergic neuron survival
- Involved in LRRK2 pathogenic pathways
- Regulates mitochondrial function through ERK signaling
- Affected by oxidative stress in PD models
¶ Stroke and Ischemia
- MEK/ERK activation in ischemic injury
- Contrasting pro-survival and pro-death roles depending on context
- Potential target for neuroprotective strategies
- Dysregulated MEK signaling in cognitive deficits
- Associated with neurodevelopmental syndromes
- Affected in some forms of intellectual disability
- Trametinib: FDA-approved for cancer, being explored for neurodegeneration
- Selumetinib: Another selective MEK1/2 inhibitor
- PD0325901: Research-grade MEK inhibitor
- Modulating synaptic plasticity in AD
- Protecting dopaminergic neurons in PD
- Reducing excitotoxic damage
- Combination with other targeted therapies
- Complex, context-dependent roles in neurons
- Potential disruption of normal neuronal function
- Blood-brain barrier penetration
- Safety concerns from long-term use
-
Thomas & Huganir (2004). MAPK cascade signalling and synaptic plasticity. Nature Reviews Neuroscience, 5(3), 173-183.
-
Seger et al. (1995). Multiple pathways in the recruitment of MAP kinases. Science Signaling, 1995(1).
-
Samuels et al. (2009). MEK-ERK signaling in neurodegeneration. Cold Spring Harbor Perspectives in Biology, 1(1), a001242.
-
Corson et al. (2003). The Ras-Raf-MEK-ERK pathway in neuronal development and plasticity. Cell Calcium, 34(4-5), 337-342.